A group from Washington University School of Medicine, Saint Louis, Missouri, United States has discovered a novel class of small molecule ketobenzothiazole TMPRSS2 inhibitors with significantly improved activity over existing irreversible inhibitors Camostat and Nafamostat. Lead compound MM3122 has an IC50 of 340 pM against recombinant full-length TMPRSS2 protein, an EC50 of 430 pM in blocking host cell entry into Calu-3 human lung epithelial cells.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204910/
